ArticleNature communications2025
Design and evolution of artificial enzyme with in-situ biosynthesized non-canonical amino acid.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing biocatalytic retrosynthesis with a graph-to-graph model.Chemical science · 2026Article
- Reprogramming NAD(P)Angewandte Chemie (International ed. in English) · 2026Article
- Advances in artificial biosynthesis of bioactive plant natural products.Current opinion in biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The creation of designer enzymes by incorporating genetically encoded non-canonical amino acids (ncAAs) could significantly expand the catalytic repertoire of the enzyme universe for abiological transformations. However, due to the limited availability of ncAAs with potential catalytic functional groups, progress in this field remains relatively slow. Herein, we present an efficient approach for enzyme design with organocatalytic ncAAs by integrating the biosynthesis and genetic incorporation of ncAAs harboring abiological catalytic residues into the protein scaffold. Based on this ncAAs in situ biosynthesis and incorporation system, our designer enzyme with an unnatural mercapto-aniline residue is created efficiently by feeding thiols to E. coli and shows significant catalytic activity for an enantioselective Friedel-Crafts alkylation reaction with excellent enantioselectivity and reactivity after directed evolution. This study provides a universal strategy for designing artificial enzymes with xenobiotic catalytic moieties with diverse biosynthesized ncAAs, thereby expanding the toolbox of biocatalysts for abiological transformations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.